{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.004","paramType":"Hazard Ratio (HR)","paramValue":"0.64","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41","upperLimit":"59","value":"49"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"80","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"Event-free survival (EFS) is measured from date of randomization to date of first: documentation of progression that render participant unable to receive planned protocol surgery, off protocol therapy for any reason without subsequent protocol surgery, failure to begin adjuvant therapy within 84 days after surgery, relapse after surgery or death due to any cause. Participants last known to be alive and event-free are censored at date of last contact. All events that occurred before the start of adjuvant therapy were assigned an event date of 84 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"Within 17 days (preferably within 14 days) days after IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG000","title":"Arm I (Adjuvant Pembrolizumab)"},{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3 cycles, then undergo surgery within 3 weeks. Within 84 days, patients receive pembrolizumab IV over 30 minutes every 3 weeks for 15 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood throughout the study and MRI or CT on study.\n\nBiospecimen Collection: Undergo collection of blood\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPembrolizumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG001","title":"Arm II (Adjuvant and Neoadjuvant Pembrolizumab)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Two-Year Event-Free Survival Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}